Overview
Vevo Therapeutics uses its Mosaic platform to generate high-resolution in vivo data for drug discovery, applying AI to analyze how drugs interact with living tissues. Its process pools cells from many patients into single tumors and performs single-cell RNA profiling to see gene expression changes across diverse populations in one experiment. This makes its data-driven insights different from traditional, cell-culture methods by capturing drug effects in real-life tissue context and across patient diversity. The company aims to make in vivo drug discovery scalable and precise so researchers can find better medicines for more patients.
Work here?Claim your company
Simplify's take
What believers are saying
- August 11, 2025 Tahoe raised $30M, signaling investor conviction after the 2022 seed.
- October 2026 job postings show hiring for machine learning, automation, and medicinal chemistry.
- South San Francisco expansion into ADCs and foundation models broadens revenue paths beyond dataset sales.
What critics are saying
- No clinical-stage asset exists; Tahoe still sells data and models, not approved medicines.
- Alloy joint venture on January 13, 2026 shifts focus toward ADCs before biology proves itself.
- Open-sourcing Tahoe-100M arms competitors like Arc, NVIDIA, and pharma partners with the core moat.
What makes Vevo Therapeutics unique
- Vevo, now Tahoe Therapeutics, built Mosaic for single-cell, multi-patient drug perturbation at scale.
- Tahoe-100M mapped 60,000 drug-cell interactions across 50 cancer lines, unmatched in public datasets.
- January 2026 Arc Institute and Biohub partnership cemented Tahoe as a virtual-cell data leader.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards